SESSION 1 - ANTIBODY-BASED DRUG DEVELOPMENT

Keynote Speaker: Davide Corti, Humabs BioMed SA a subsidiary of Vir Biotechnology

Andreas Laustsen, Technical University of Denmark, Denmark
VIR speaker, Vir Biotechnology
Anna Codina, Bruker Biospin - from BRUKER
Bernard Vanhove, CSO, Xenothera
Selected abstracts for oral presentations
Poster Session

SESSION 2 - NANOMEDICINE AGAINST INFECTIOUS DISEASES

Donata Medaglini, University of Siena, Italy
Jennifer Grossman, National Institute of Health, USA

SESSION 3 - IMMUNOTHERAPY AGAINST EMERGING INFECTIOUS DISEASES

Keynote Speaker: Antonio Lanzavecchia, IRB, Switzerland

Lisa Purcell from REGENERON
Luca Varani, IRB, Switzerland
Keynote Speaker: Man-Wah Tan, Genentech, USA

SESSION 4 - IMMUNOTHERAPY AGAINST VIRAL INFECTIONS

Keynote Speaker: Hugo Mouquet, Institut Pasteur, France

Pongrama Ramasoota, Mahidol University, Bangkok, Thailand
Nancy Haigwood, Oregon National Primate Research Center, Oregon Health and Science University, USA
Fausto Baldanti, Policlinico San Matteo, IRCCS, Pavia, Italy
Selected abstracts for oral presentations
Poster Session

SESSION 5 - IMMUNOTHERAPY AGAINST BACTERIAL INFECTIONS

Keynote Speaker: Larry Zeitlin, Mapp Biopharmaceutical, USA

Bernhard B. Singer, University Hospital Essen, Germany
Theam Soon Lim, University SainsMalaysia (USM), Penang, Malaysia
Michael Hust, Technische Universität Braunschweig, Germany
Selected abstracts for oral presentations

SESSION 6 - PRODUCTION AND REGULATORY CHALLENGES

Sumathi Nambiar, U.S. Food and Drug and Administration
Leander Grode, VPM GmbH, Hannover, Germany
Marisa Papaluca, former senior scientist, European Medicinal Agency

SESSION 7 - 3RS PRINCIPLES IN BIOTECHNOLOGICAL AND MEDICAL APPLICATIONS

Laura Gribaldo, Scientific Officer, European Commission Joint Research Centre
Jeff Brown, PETA International Science Consortium Ltd., UK
Ida Retter, Charité, Berlin, Germany

12:00-12:15 CONCLUSIONS AND REMARKS